These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38819395)

  • 1. Efficacy and Safety of Donidalorsen for Hereditary Angioedema.
    Riedl MA; Tachdjian R; Lumry WR; Craig T; Karakaya G; Gelincik A; Stobiecki M; Jacobs JS; Gokmen NM; Reshef A; Gompels MM; Manning ME; Bordone L; Newman KB; Treadwell S; Wang S; Yarlas A; Cohn DM;
    N Engl J Med; 2024 Jul; 391(1):21-31. PubMed ID: 38819395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Prekallikrein for Hereditary Angioedema.
    Fijen LM; Riedl MA; Bordone L; Bernstein JA; Raasch J; Tachdjian R; Craig T; Lumry WR; Manning ME; Alexander VJ; Newman KB; Revenko A; Baker BF; Nanavati C; MacLeod AR; Schneider E; Cohn DM
    N Engl J Med; 2022 Mar; 386(11):1026-1033. PubMed ID: 35294812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.
    Petersen RS; Bordone L; Riedl MA; Tachdjian R; Craig TJ; Lumry WR; Manning ME; Bernstein JA; Raasch J; Zuraw BL; Deng Y; Newman KB; Alexander VJ; Lui C; Schneider E; Cohn DM
    Allergy; 2024 Mar; 79(3):724-734. PubMed ID: 38009241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Craig TJ; Reshef A; Li HH; Jacobs JS; Bernstein JA; Farkas H; Yang WH; Stroes ESG; Ohsawa I; Tachdjian R; Manning ME; Lumry WR; Saguer IM; Aygören-Pürsün E; Ritchie B; Sussman GL; Anderson J; Kawahata K; Suzuki Y; Staubach P; Treudler R; Feuersenger H; Glassman F; Jacobs I; Magerl M
    Lancet; 2023 Apr; 401(10382):1079-1090. PubMed ID: 36868261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
    Banerji A; Riedl MA; Bernstein JA; Cicardi M; Longhurst HJ; Zuraw BL; Busse PJ; Anderson J; Magerl M; Martinez-Saguer I; Davis-Lorton M; Zanichelli A; Li HH; Craig T; Jacobs J; Johnston DT; Shapiro R; Yang WH; Lumry WR; Manning ME; Schwartz LB; Shennak M; Soteres D; Zaragoza-Urdaz RH; Gierer S; Smith AM; Tachdjian R; Wedner HJ; Hebert J; Rehman SM; Staubach P; Schranz J; Baptista J; Nothaft W; Maurer M;
    JAMA; 2018 Nov; 320(20):2108-2121. PubMed ID: 30480729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Craig T; Magerl M; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Pawaskar D; Jacobs I; Pragst I; Doyle MK
    Lancet; 2022 Mar; 399(10328):945-955. PubMed ID: 35219377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
    Craig TJ; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Alexandru Bica M; Jacobs I; Pragst I; Magerl M
    Lancet Haematol; 2024 Jun; 11(6):e436-e447. PubMed ID: 38710185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
    Zuraw B; Lumry WR; Johnston DT; Aygören-Pürsün E; Banerji A; Bernstein JA; Christiansen SC; Jacobs JS; Sitz KV; Gower RG; Gagnon R; Wedner HJ; Kinaciyan T; Hakl R; Hanzlíková J; Anderson JT; McNeil DL; Fritz SB; Yang WH; Tachdjian R; Busse PJ; Craig TJ; Li HH; Farkas H; Best JM; Clemons D; Cornpropst M; Dobo SM; Iocca HA; Kargl D; Nagy E; Murray SC; Collis P; Sheridan WP; Maurer M; Riedl MA
    J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema.
    Cohn DM; Viney NJ; Fijen LM; Schneider E; Alexander VJ; Xia S; Kaeser GE; Nanavati C; Baker BF; Geary RS; Levi M; Meijers JCM; Stroes ESG
    N Engl J Med; 2020 Sep; 383(13):1242-1247. PubMed ID: 32877578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
    Aygören-Pürsün E; Zanichelli A; Cohn DM; Cancian M; Hakl R; Kinaciyan T; Magerl M; Martinez-Saguer I; Stobiecki M; Farkas H; Kiani-Alikhan S; Grivcheva-Panovska V; Bernstein JA; Li HH; Longhurst HJ; Audhya PK; Smith MD; Yea CM; Maetzel A; Lee DK; Feener EP; Gower R; Lumry WR; Banerji A; Riedl MA; Maurer M
    Lancet; 2023 Feb; 401(10375):458-469. PubMed ID: 36774155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
    Riedl MA; Aygören-Pürsün E; Baker J; Farkas H; Anderson J; Bernstein JA; Bouillet L; Busse P; Manning M; Magerl M; Gompels M; Huissoon AP; Longhurst H; Lumry W; Ritchie B; Shapiro R; Soteres D; Banerji A; Cancian M; Johnston DT; Craig TJ; Launay D; Li HH; Liebhaber M; Nickel T; Offenberger J; Rae W; Schrijvers R; Triggiani M; Wedner HJ; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan WP; Maurer M
    Allergy; 2018 Sep; 73(9):1871-1880. PubMed ID: 29688579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
    Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
    N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
    Longhurst H; Cicardi M; Craig T; Bork K; Grattan C; Baker J; Li HH; Reshef A; Bonner J; Bernstein JA; Anderson J; Lumry WR; Farkas H; Katelaris CH; Sussman GL; Jacobs J; Riedl M; Manning ME; Hebert J; Keith PK; Kivity S; Neri S; Levy DS; Baeza ML; Nathan R; Schwartz LB; Caballero T; Yang W; Crisan I; Hernandez MD; Hussain I; Tarzi M; Ritchie B; Králíčková P; Guilarte M; Rehman SM; Banerji A; Gower RG; Bensen-Kennedy D; Edelman J; Feuersenger H; Lawo JP; Machnig T; Pawaskar D; Pragst I; Zuraw BL;
    N Engl J Med; 2017 Mar; 376(12):1131-1140. PubMed ID: 28328347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.
    Aygören-Pürsün E; Bygum A; Grivcheva-Panovska V; Magerl M; Graff J; Steiner UC; Fain O; Huissoon A; Kinaciyan T; Farkas H; Lleonart R; Longhurst HJ; Rae W; Triggiani M; Aberer W; Cancian M; Zanichelli A; Smith WB; Baeza ML; Du-Thanh A; Gompels M; Gonzalez-Quevedo T; Greve J; Guilarte M; Katelaris C; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan W; Maurer M; Cicardi M
    N Engl J Med; 2018 Jul; 379(4):352-362. PubMed ID: 30044938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
    Ohsawa I; Honda D; Suzuki Y; Fukuda T; Kohga K; Morita E; Moriwaki S; Ishikawa O; Sasaki Y; Tago M; Chittick G; Cornpropst M; Murray SC; Dobo SM; Nagy E; Van Dyke S; Reese L; Best JM; Iocca H; Collis P; Sheridan WP; Hide M
    Allergy; 2021 Jun; 76(6):1789-1799. PubMed ID: 33247955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
    Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
    N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies.
    Farkas H; Balla Z
    Expert Opin Investig Drugs; 2024 Mar; 33(3):191-200. PubMed ID: 38366937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
    Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
    Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial.
    Riedl MA; Grivcheva-Panovska V; Moldovan D; Baker J; Yang WH; Giannetti BM; Reshef A; Andrejevic S; Lockey RF; Hakl R; Kivity S; Harper JR; Relan A; Cicardi M
    Lancet; 2017 Sep; 390(10102):1595-1602. PubMed ID: 28754491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
    Levy RJ; Lumry WR; McNeil DL; Li HH; Campion M; Horn PT; Pullman WE
    Ann Allergy Asthma Immunol; 2010 Jun; 104(6):523-9. PubMed ID: 20568386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.